About MDI Bioscience
MDI Bioscience combines world-class expertise and non-mammalian disease models for target-based in vivo profiling of new drug compounds in whole organisms. Our assays deliver important data on the efficacy and organ toxicity of early-stage molecules before the initiation of costly and time-consuming mammalian studies. We use state-of-the-art gene-editing approaches like CRISPR to develop custom knock-in and knock-out models and transgenic biosensors in zebrafish, zebrafish larvae, and C. elegans. Assessing these models with high throughput imaging allows for faster screening of a greater number of compounds than would be possible with conventional mammalian models.Learn More
Custom zebrafish, zebrafish embryos, and C. elegans basic research and lead discovery.
Organoids and stem cell-based organ-on-a-chip technologies tailored to your target.
Statistical and multivariate analyses to deliver clear and actionable study data and analysis.
Rapid screening of large compound libraries and phenotypic drug development.